Renal Cell Carcinoma Perspective

 
 
  • Highlights in Metastatic Kidney Cancer Treatment From IKCS 2022   Highlights in kidney cancer from IKCS 2022 include updates on the CLEAR and CheckMate 214 trials, results from the TIVO-3 trial, and early data on a bacterial supplement to enhance immune therapy.
  • Episode 4: The Microbiome and Renal Cell Carcinoma   Drs Sumanta Pal and Jennifer Wargo discuss how the gut microbiome impacts response to cancer therapy in patients with renal cell carcinoma.
  • RCC e-Tumor Boards: Case 3: Non-Clear Cell RCC   This case is of a 70-year-old man who initially presents with a right renal mass on a nuclear stress test and is diagnosed with non-clear cell RCC. The team discusses the benefits of genetic testing, hereditary concerns, new treatments, and surgery considerations.
  • Episode 3: Non-Clear Cell Renal Cell Carcinoma   Drs Sumanta Pal and Mehmet Asim Bilen discuss the complexities of treating patients with non-clear cell renal carcinoma, the nuances of rare subtypes, and when to use chemotherapy vs immunotherapy.
  • Updates in Renal Cell Carcinoma From ESMO 2022   Positive results with triplet therapy, three adjuvant immunotherapy failures, and promising novel combinations are some of the updates from ESMO Congress 2022 discussed by Dr Eric Jonasch.
  • Episode 2: Adjuvant Treatment With Immunotherapy   Drs Sumanta Pal and Tian Zhang review the state of the data on adjuvant treatment with immunotherapy for patients with renal cell carcinoma, including where current clinical trials stand.
  • Episode 1: Frontline Treatment of Renal Cell Carcinoma   Drs Sumanta Pal and Brian Rini discuss frontline treatment of renal cell carcinoma.
  • Episode 1: Bladder Cancer Choices: Robotic or Open Cystectomy?   Bladder cancer surgeons Drs Cheryl Lee and Khurshid Guru are inspired by a recent Swedish study and discuss aggregate surgical outcomes data comparing their own different approaches.
  • Highlights in Renal Cell Carcinoma From ASCO 2022   Dr Brian Rini, of Vanderbilt University, reports on key studies in renal cell cancer from ASCO 2022, including results from the EVEREST and CheckMate 9ER trials, and data on a novel AXL inhibitor.
  • EAU 2022 Read clinically focused news coverage of key developments from EAU 2022
  • RCC e-Tumor Boards: Case 2: High-Risk Localized RCC   The Kidney Cancer Team from Memorial Sloan Kettering Cancer Center discusses adjuvant treatment strategies for a patient with high-risk localized RCC.
  • AUA 2022 Read clinically focused news coverage of key developments from AUA 2022
  • Renal Cell Carcinoma Highlights From ASCO-GU 2022   The role of immunotherapy at various disease stages and the predictive power of preoperative sarcopenia are among the highlights in renal cell carcinoma from ASCO-GU 2022 reviewed by Dr Brian Shuch.
  • GUCS 2022 Read clinically focused news coverage of key developments from GUCS 2022
  • Renal Cell Carcinoma: Achieving Complete Response   "One of the most gratifying patient experiences that I've had," says Sandy Srinivas in recounting a patient with RCC who achieved a complete response.
  • The Evolution of Treatment Options in Renal Cell Carcinoma   Eric Jonasch, MD, follows the trajectory of RCC treatments that have been developed during his career.
  • Renal Cell Carcinoma: A Flourishing Landscape   "I've been taking care of patients with kidney cancer now for more than 25 years, and a lot has changed in this field," says Sandy Srinivas in recalling an experience with an RCC patient in 2011.
  • Advice on Managing Advanced Renal Cell Carcinoma: Think Prospectively and Never Give Up   "Never give up," says Eric Jonasch, MD, in recalling a patient with metastatic ccRCC who started responding to therapy after progressing through three lines of treatment.
  • Find Individuals That Inspire You   Eric Jonasch, MD, reflects on the impact that his mentor had on his philosophy and approach to the treatment of patients with renal cell carcinoma.
  • Unmet Needs in the Era of Precision Medicine for RCC   Sandy Srinivas, MD, examines the current unmet needs for patients with renal cell carcinoma and discusses how the KEYNOTE-564 trial can help identify the right patient for the right therapy.